Table 1.
Basic information of the included studies
| Study | Country | Case (T/C, n) | Age (T/C, y) | Sex (M/F) | Diagnosis | Chemotherapy | Lentinan | Follow‐up |
|---|---|---|---|---|---|---|---|---|
| Cai et al. 11 | China | 30/34 | 59 (31–82) | 47/17 | Advanced lung cancer | DNR + ADM + CTX + DDP | 2 mg, twice a week | 8 weeks |
| Ina et al. 12 | Japan | 31/37 | 67/68 | 48/20 | Metastatic/recurrent GC | Paclitaxel + S−1 + DDP | 2 mg, twice a month | 6 years |
| Guo et al. 13 | China | 20/20 | 56 (23–75) | 23/17 | Lung cancer + GC | 5‐FU + ADM + MMC + DNR + DDP | 1 mg, twice a week | 8 weeks |
| Ma et al. 14 | China | 43/42 | 62.6 ± 5.7 | 40/45 | Advanced GI cancer | Javanica oil emulsion | 1 mg, twice a week | 8 weeks |
| Yoshino et al. 15 | Japan | 149/146 | 73/74 | 208/87 | Unresectable/recurrent GC | S‐1 | 2 mg, once a week | 12 months |
| Nakano et al. 16 | Japan | 23/22 | 63/66 | 34/11 | Unresectable/recurrent GC | Tegafur + DDP | 2 mg, every day | 22 months |
| Ochiai et al. 17 | Japan | 45/44 | 60/63 | 62/27 | Advanced/recurrent GC | Tegafur + MMC | 2 mg, once a week | >2 years |
| Suto et al. 18 | Japan | 15/16 | 62/66 | 21/10 | HCC | 5‐FU | 2 mg, once a week | >3 years |
| Taguchi et al. 19 | Japan | 111/104 | 61/59 | 151/64 | Advanced/recurrent GC | 5‐FU + MMC | 2 mg, once a week | >4 years |
| Wu et al. 20 | China | 40/40 | 68 (55–80) | 49/31 | Advanced GC | 5‐FU + DDP + docetaxel | 1 mg, twice a week | 4 weeks |
| Wang et al. 21 | China | 25/25 | 60/61 | 30/20 | Esophagus cancer | Tegafur | 1 mg, every 2 days | 6 weeks |
| Wakui et al. 22 | Japan | 20/22 | <80 | 26/16 | Advanced GC and colorectal cancer | Tegafur | 2 mg, once a week | >4 years |
| Yang et al. 23 | China | 31/24 | 60/59 | 41/14 | HCC | Epirubicin + HCPT | 500 mg, every day | 18 months |
| Li et al. 24 | China | 40/40 | 58 (25–70) | 48/32 | Advanced GC | Paclitaxel + 5‐FU + DDP | 2 mg, once a week | 6 weeks |
| Pan et al. 25 | China | 23/20 | 53 (21–74) | 34/9 | Advanced lung cancer + GC | 5‐FU + ADM + MMC + CTX + VCR | 1 mg, twice a week | 3 months |
| Song et al. 26 | China | 30/30 | 65 (60–67) | 48/12 | Advanced lung cancer | MMC + VCR + DDP | 2 mg, twice a week | 8 weeks |
| Wang et al. 27 | China | 42/39 | >18 | 65/16 | Advanced lung cancer | NVP + DDP | 1 mg, twice a week | 8 weeks |
T, treatment group; C, control group; M, male; F, female; GI, gastrointestinal; GC, gastric cancer; HCC, hepatocellular carcinoma; ADM, adriamycin; CTX, cyclophosphamide; DDP, cisplatin; DNR, daunorubicin; 5‐FU, fluorouracil; HCPT, hydroxycamptothecin, MMC, mitomycin C; VCR, vincristine; NVP, vinorelbine.